Scotia Capital Inc. Invests $55,000 in FSD Pharma Inc. (NASDAQ:HUGE)

Scotia Capital Inc. bought a new stake in shares of FSD Pharma Inc. (NASDAQ:HUGEFree Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 61,273 shares of the company’s stock, valued at approximately $55,000. Scotia Capital Inc. owned about 0.16% of FSD Pharma at the end of the most recent reporting period.

Analyst Upgrades and Downgrades

Separately, Singular Research reiterated a “buy-venture” rating on shares of FSD Pharma in a research report on Tuesday, May 7th.

Get Our Latest Research Report on HUGE

FSD Pharma Price Performance

Shares of HUGE opened at $0.26 on Friday. The company has a 50-day moving average of $0.43 and a two-hundred day moving average of $0.75. The stock has a market cap of $10.39 million, a price-to-earnings ratio of -1.00 and a beta of 0.66. FSD Pharma Inc. has a one year low of $0.22 and a one year high of $1.68.

FSD Pharma (NASDAQ:HUGEGet Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05). Analysts anticipate that FSD Pharma Inc. will post -0.22 earnings per share for the current year.

About FSD Pharma

(Free Report)

FSD Pharma Inc, a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders.

Recommended Stories

Receive News & Ratings for FSD Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FSD Pharma and related companies with MarketBeat.com's FREE daily email newsletter.